TWI695013B - 抗體、產生該抗體之融合瘤、包含該抗體之藥學組成物及其用途 - Google Patents

抗體、產生該抗體之融合瘤、包含該抗體之藥學組成物及其用途 Download PDF

Info

Publication number
TWI695013B
TWI695013B TW106128651A TW106128651A TWI695013B TW I695013 B TWI695013 B TW I695013B TW 106128651 A TW106128651 A TW 106128651A TW 106128651 A TW106128651 A TW 106128651A TW I695013 B TWI695013 B TW I695013B
Authority
TW
Taiwan
Prior art keywords
amino acid
acid sequence
seq
antibody
antigen
Prior art date
Application number
TW106128651A
Other languages
English (en)
Chinese (zh)
Other versions
TW201738276A (zh
Inventor
游丞德
賴建勳
陳怡如
王正琪
蔡易芊
Original Assignee
台灣浩鼎生技股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 台灣浩鼎生技股份有限公司 filed Critical 台灣浩鼎生技股份有限公司
Publication of TW201738276A publication Critical patent/TW201738276A/zh
Application granted granted Critical
Publication of TWI695013B publication Critical patent/TWI695013B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/38—Post-translational modifications [PTMs] in chemical analysis of biological material addition of carbohydrates, e.g. glycosylation, glycation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
TW106128651A 2014-04-10 2015-04-10 抗體、產生該抗體之融合瘤、包含該抗體之藥學組成物及其用途 TWI695013B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461977824P 2014-04-10 2014-04-10
US61/977,824 2014-04-10
US201462057381P 2014-09-30 2014-09-30
US62/057,381 2014-09-30

Publications (2)

Publication Number Publication Date
TW201738276A TW201738276A (zh) 2017-11-01
TWI695013B true TWI695013B (zh) 2020-06-01

Family

ID=54288553

Family Applications (3)

Application Number Title Priority Date Filing Date
TW106128651A TWI695013B (zh) 2014-04-10 2015-04-10 抗體、產生該抗體之融合瘤、包含該抗體之藥學組成物及其用途
TW106128654A TWI697503B (zh) 2014-04-10 2015-04-10 抗體、產生該抗體之融合瘤、包含該抗體之藥學組成物及其用途
TW104111557A TWI609886B (zh) 2014-04-10 2015-04-10 抗體、產生該抗體之融合瘤、包含該抗體之藥學組成物及其用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW106128654A TWI697503B (zh) 2014-04-10 2015-04-10 抗體、產生該抗體之融合瘤、包含該抗體之藥學組成物及其用途
TW104111557A TWI609886B (zh) 2014-04-10 2015-04-10 抗體、產生該抗體之融合瘤、包含該抗體之藥學組成物及其用途

Country Status (17)

Country Link
US (2) US9902779B2 (enExample)
EP (2) EP3662928A1 (enExample)
JP (1) JP2017512759A (enExample)
KR (1) KR101966408B1 (enExample)
CN (2) CN112390887B (enExample)
AU (2) AU2015243246B2 (enExample)
BR (1) BR112016020009A2 (enExample)
CA (2) CA2941029C (enExample)
CL (1) CL2016002569A1 (enExample)
ES (1) ES2772817T3 (enExample)
IL (2) IL246837B (enExample)
PH (1) PH12016501976A1 (enExample)
RU (1) RU2016138744A (enExample)
SG (1) SG11201607258SA (enExample)
TW (3) TWI695013B (enExample)
WO (1) WO2015157629A2 (enExample)
ZA (1) ZA201605175B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6431920B2 (ja) 2013-09-17 2018-11-28 オービーアイ ファーマ，インコーポレイテッド 免疫反応を誘導する炭水化物ワクチンの組成とがんの治療におけるその使用
WO2015143126A1 (en) 2014-03-19 2015-09-24 Mackay Memorial Hospital Of Taiwan Presbyterian Church And Mackay Memorial Social Work Foundation Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof
SG11201607258SA (en) 2014-04-10 2016-10-28 Obi Pharma Inc Antibodies, pharmaceutical compositions and uses thereof
JP2018532990A (ja) 2015-09-04 2018-11-08 オービーアイ ファーマ，インコーポレイテッド グリカンアレイおよび使用の方法
CA3000531A1 (en) * 2015-10-07 2017-04-13 Obi Pharma, Inc. Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof
WO2017172990A1 (en) 2016-03-29 2017-10-05 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
MY200886A (en) 2016-04-22 2024-01-22 Obi Pharma Inc Cancer Immunotherapy by Immune Activation or Immune Modulation Via Globo Series Antigens
GB201612317D0 (en) 2016-07-15 2016-08-31 Philogen Spa Antibody compositions
JP2019527690A (ja) 2016-07-27 2019-10-03 オービーアイ ファーマ，インコーポレイテッド 免疫原性／治療用グリカン組成物およびその使用
US11643456B2 (en) 2016-07-29 2023-05-09 Obi Pharma, Inc. Human antibodies, pharmaceutical compositions and methods
TWI767959B (zh) * 2016-11-21 2022-06-21 台灣浩鼎生技股份有限公司 共軛生物分子、醫藥組成物及方法
CA3064443A1 (en) * 2017-05-24 2018-11-29 Development Center For Biotechnology Humanized antibodies against globo h and uses thereof in cancer treatments
CN112566642B (zh) * 2018-03-14 2025-01-17 纪念斯隆凯特琳癌症中心 抗聚唾液酸抗体及其用途
TW202016147A (zh) * 2018-06-01 2020-05-01 台灣浩鼎生技股份有限公司 使用抗Globo H或抗SSEA-4抗體與抗負面免疫檢查點抗體之結合醫療
WO2020006176A1 (en) 2018-06-27 2020-01-02 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
US20250327822A1 (en) * 2019-03-28 2025-10-23 Ming-Tain Lai Companion diagnostic assay for globo-h related cancer therapy
WO2022173772A1 (en) * 2021-02-09 2022-08-18 Obi Pharma, Inc. Globo series antigens-binding chimeric antigen receptors and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060165695A1 (en) * 2002-04-30 2006-07-27 Kenya Shitara Antibody against human insulin-like growth factor
TW201100098A (en) * 2009-06-16 2011-01-01 Academia Sinica Globo H and related anti-cancer vaccines with novel glycolipid adjuvants
US20130344089A1 (en) * 2011-03-08 2013-12-26 Alzinova Ab Anti oligomer antibodies and uses thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
EP1150710B1 (en) 1999-02-17 2010-04-21 Csl Limited Immunogenic complexes and methods relating thereto
EP1266014A2 (en) 2000-03-24 2002-12-18 Peter Kufer Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
CU23007A1 (es) * 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
EP1293514B1 (en) * 2001-09-14 2006-11-29 Affimed Therapeutics AG Multimeric single chain tandem Fv-antibodies
BR0107262B1 (pt) 2001-12-17 2014-04-22 Da Fonseca Clovis Orlando Pereira Composição farmacêutica inalatória
US20040126829A1 (en) 2001-12-18 2004-07-01 Hildebrand William H. Anti-HLA assay and methods
JP4524181B2 (ja) * 2002-05-30 2010-08-11 マクロジェニクス，インコーポレーテッド Ｃｄ１６ａ結合タンパク質および免疫障害治療のための使用
AT413486B (de) * 2002-07-03 2006-03-15 Igeneon Krebs Immuntherapie Verwendung eines antikörpers gerichtet gegen lewis-antigene
DK1766093T3 (da) 2004-02-06 2011-10-03 Univ Massachusetts Antistoffer mod clostridium difficile-toksiner og anvendelse deraf
DK2287195T3 (da) * 2004-07-01 2019-08-19 Innate Pharma Pan-kir2dl nk-receptor-antistoffer og anvendelse heraf i diagnostik og terapi
JP2008506683A (ja) 2004-07-18 2008-03-06 コーリー ファーマシューティカル グループ， リミテッド 先天免疫応答を誘導するための方法および組成物
KR20100018029A (ko) 2004-07-18 2010-02-16 씨에스엘 리미티드 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기 위한 올리고뉴클레오티드 제제
HRP20110859T1 (hr) * 2004-12-21 2011-12-31 Medimmune Limited Protutijela usmjerena na angiopoietin-2 i njihova upotreba
EP2402374A1 (en) * 2005-02-07 2012-01-04 GlycArt Biotechnology AG Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
ES2657443T3 (es) * 2005-03-25 2018-03-05 Gitr, Inc. Anticuerpos anti-GITR y usos de los mismos
CL2007002668A1 (es) * 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
EP1920781B1 (en) 2006-11-10 2015-03-04 Glycotope GmbH Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors
US20100145032A1 (en) * 2007-01-18 2010-06-10 Suomen Punainen Risti, Veripalelu Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof
CA2728344A1 (en) 2008-06-16 2010-01-14 Academia Sinica Compositions for inducing immune responses specific to globo h and ssea3 and uses thereof in cancer treatment
MX2010013931A (es) 2008-06-16 2011-06-01 Academia Sinica Diagnosis de cancer basada en niveles de anticuerpos contra globo h y sus fragmentos.
JP5769316B2 (ja) * 2009-08-06 2015-08-26 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
WO2011136911A2 (en) * 2010-04-09 2011-11-03 Aveo Pharmaceuticals, Inc. Anti-erbb3 antibodies
US8945898B2 (en) 2010-07-01 2015-02-03 Dsm Ip Assets B.V. Recombinant host cell with deficiency in non-ribosomal peptide synthase production
CA2808382A1 (en) * 2010-08-16 2012-02-23 Amgen Inc. Antibodies that bind myostatin, compositions and methods
US20120275996A1 (en) * 2010-12-21 2012-11-01 Abbott Laboratories IL-1 Binding Proteins
US9828635B2 (en) 2011-10-06 2017-11-28 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-ERBB3 antibodies
ES2812849T3 (es) 2012-02-24 2021-03-18 Abbvie Stemcentrx Llc Anticuerpos anti-DLL3 y procedimientos de utilización de los mismos
KR20160104727A (ko) 2014-01-16 2016-09-05 아카데미아 시니카 암의 치료 및 검출을 위한 조성물 및 방법
WO2015143126A1 (en) 2014-03-19 2015-09-24 Mackay Memorial Hospital Of Taiwan Presbyterian Church And Mackay Memorial Social Work Foundation Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof
SG11201607258SA (en) 2014-04-10 2016-10-28 Obi Pharma Inc Antibodies, pharmaceutical compositions and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060165695A1 (en) * 2002-04-30 2006-07-27 Kenya Shitara Antibody against human insulin-like growth factor
TW201100098A (en) * 2009-06-16 2011-01-01 Academia Sinica Globo H and related anti-cancer vaccines with novel glycolipid adjuvants
US20130344089A1 (en) * 2011-03-08 2013-12-26 Alzinova Ab Anti oligomer antibodies and uses thereof

Also Published As

Publication number Publication date
ES2772817T3 (es) 2020-07-08
IL246837B (en) 2020-08-31
TW201738277A (zh) 2017-11-01
IL276695B (en) 2021-09-30
CA3104268A1 (en) 2015-10-15
KR101966408B1 (ko) 2019-04-05
KR20160137984A (ko) 2016-12-02
RU2016138744A (ru) 2018-05-11
PH12016501976A1 (en) 2016-12-19
US9902779B2 (en) 2018-02-27
EP3129048A2 (en) 2017-02-15
AU2018253589B2 (en) 2020-04-16
AU2015243246B2 (en) 2018-09-06
WO2015157629A2 (en) 2015-10-15
AU2018253589A1 (en) 2018-11-22
IL246837A0 (en) 2016-08-31
TW201738276A (zh) 2017-11-01
BR112016020009A2 (pt) 2017-10-17
TWI697503B (zh) 2020-07-01
US20180134799A1 (en) 2018-05-17
CN112390887B (zh) 2023-09-26
EP3662928A1 (en) 2020-06-10
CN106456727B (zh) 2020-11-27
RU2016138744A3 (enExample) 2018-05-11
CN106456727A (zh) 2017-02-22
CL2016002569A1 (es) 2017-09-08
AU2015243246A1 (en) 2016-09-08
ZA201605175B (en) 2017-09-27
CA2941029C (en) 2021-02-16
JP2017512759A (ja) 2017-05-25
EP3129048B1 (en) 2020-01-15
EP3129048A4 (en) 2017-10-25
CN112390887A (zh) 2021-02-23
US20170029526A1 (en) 2017-02-02
WO2015157629A3 (en) 2015-12-03
CA2941029A1 (en) 2015-10-15
TWI609886B (zh) 2018-01-01
IL276695A (en) 2020-09-30
US10815307B2 (en) 2020-10-27
TW201546092A (zh) 2015-12-16
SG11201607258SA (en) 2016-10-28

Similar Documents

Publication Publication Date Title
TWI695013B (zh) 抗體、產生該抗體之融合瘤、包含該抗體之藥學組成物及其用途
CN112533955B (zh) 抗b7-h3抗体
US11236154B2 (en) Carbohydrate antibodies, pharmaceutical compositions and uses thereof
TWI811604B (zh) 抗體、醫藥組成物及其用途
TW201909926A (zh) Ｂ７ｈ３抗體－藥物偶聯物及其醫藥用途
KR20160131082A (ko) Lg1-3에 특이적인 항-라미닌4 항체
TW201718641A (zh) 抗血管內皮生長因子受體２（ｖｅｇｆｒ２）抗體
CN112312924A (zh) 通过使用抗Globo H或抗SSEA-4抗体与抗负面免疫检查点抗体的联合疗法
KR20190130506A (ko) 골수유래억제세포 관련 질환의 예방 및 치료 용도
HK40037463A (en) Antibodies, hybridoma producing such antibodies and uses thereof
HK40037463B (zh) 抗体、产生所述抗体的杂交瘤、及其用途
WO2024125331A1 (en) ANTIBODIES AGAINST SIRPα AND USES THEREOF
HK1232767A1 (en) Antibodies, hybridoma producing such antibodies and uses thereof
HK1232767B (zh) 抗体、产生所述抗体的杂交瘤、及其用途
TW202302635A (zh) Ｉｌ－３８專一性抗體
HK40042120A (en) Combination therapy by using anti-globo h or anti-ssea-4 antibody with anti-negative immune check points antibody
WO2019221574A1 (ko) 골수유래억제세포 관련 질환의 예방 및 치료 용도